• Mashup Score: 2

    Angelman syndrome is a rare neurodevelopmental disorder caused by a genetic mutation – usually a mutation in the ubiquitin protein ligase E3a (UBE3A) gene – that leads to a reduction in UBE3A protein.

    Tweet Tweets with this article
    • Dr. Amit Rahkit, CMO at Ovid Therapeutics Inc. discusses OV101, a GABAA agonist that is showing promise in clinical trials for Angelman syndrome. @OvidRx @angelman @AngelmanUK Angelman Syndrome International Angelman Day https://t.co/ejMNg9HHVz

  • Mashup Score: 2

    Angelman syndrome is a rare neurodevelopmental disorder caused by a genetic mutation – usually a mutation in the ubiquitin protein ligase E3a (UBE3A) gene – that leads to a reduction in UBE3A protein.

    Tweet Tweets with this article
    • Dr. Amit Rahkit, CMO at Ovid Therapeutics Inc. discusses OV101, a GABAA agonist that is showing promise in clinical trials for Angelman syndrome. @OvidRx @angelman @AngelmanUK Angelman Syndrome International Angelman Day https://t.co/ejMNg9HHVz

  • Mashup Score: 2

    Angelman syndrome is a rare neurodevelopmental disorder caused by a genetic mutation – usually a mutation in the ubiquitin protein ligase E3a (UBE3A) gene – that leads to a reduction in UBE3A protein.

    Tweet Tweets with this article
    • Dr. Amit Rahkit, CMO at Ovid Therapeutics Inc. discusses OV101, a GABAA agonist that is showing promise in clinical trials for Angelman syndrome. @OvidRx @angelman @AngelmanUK Angelman Syndrome International Angelman Day https://t.co/ejMNg9HHVz

  • Mashup Score: 2

    Angelman syndrome is a rare neurodevelopmental disorder caused by a genetic mutation – usually a mutation in the ubiquitin protein ligase E3a (UBE3A) gene – that leads to a reduction in UBE3A protein.

    Tweet Tweets with this article
    • Dr. Amit Rahkit, CMO at Ovid Therapeutics Inc. discusses OV101, a GABAA agonist that is showing promise in clinical trials for Angelman syndrome. @OvidRx @angelman @AngelmanUK Angelman Syndrome International Angelman Day https://t.co/ejMNg9HHVz

  • Mashup Score: 2

    Angelman syndrome is a rare neurodevelopmental disorder caused by a genetic mutation – usually a mutation in the ubiquitin protein ligase E3a (UBE3A) gene – that leads to a reduction in UBE3A protein.

    Tweet Tweets with this article
    • Dr. Amit Rahkit, CMO at Ovid Therapeutics Inc. discusses OV101, a GABAA agonist that is showing promise in clinical trials for Angelman syndrome. @OvidRx @angelman @AngelmanUK Angelman Syndrome International Angelman Day https://t.co/ejMNg9HHVz

  • Mashup Score: 2

    Angelman syndrome is a rare neurodevelopmental disorder caused by a genetic mutation – usually a mutation in the ubiquitin protein ligase E3a (UBE3A) gene – that leads to a reduction in UBE3A protein.

    Tweet Tweets with this article
    • Dr. Amit Rahkit, CMO at Ovid Therapeutics Inc. discusses OV101, a GABAA agonist that is showing promise in clinical trials for Angelman syndrome. @OvidRx @angelman @AngelmanUK Angelman Syndrome International Angelman Day https://t.co/ejMNg9HHVz

  • Mashup Score: 2

    Angelman syndrome is a rare neurodevelopmental disorder caused by a genetic mutation – usually a mutation in the ubiquitin protein ligase E3a (UBE3A) gene – that leads to a reduction in UBE3A protein.

    Tweet Tweets with this article
    • Dr. Amit Rahkit, CMO at Ovid Therapeutics Inc. discusses OV101, a GABAA agonist that is showing promise in clinical trials for Angelman syndrome. @OvidRx @angelman @AngelmanUK Angelman Syndrome International Angelman Day https://t.co/ejMNg9HHVz

  • Mashup Score: 2

    Angelman syndrome is a rare neurodevelopmental disorder caused by a genetic mutation – usually a mutation in the ubiquitin protein ligase E3a (UBE3A) gene – that leads to a reduction in UBE3A protein.

    Tweet Tweets with this article
    • Dr. Amit Rahkit, CMO at Ovid Therapeutics Inc. discusses OV101, a GABAA agonist that is showing promise in clinical trials for Angelman syndrome. @OvidRx @angelman @AngelmanUK Angelman Syndrome International Angelman Day https://t.co/ejMNg9HHVz

  • Mashup Score: 2

    Angelman syndrome is a rare neurodevelopmental disorder caused by a genetic mutation – usually a mutation in the ubiquitin protein ligase E3a (UBE3A) gene – that leads to a reduction in UBE3A protein.

    Tweet Tweets with this article
    • Dr. Amit Rahkit, CMO at Ovid Therapeutics Inc. discusses OV101, a GABAA agonist that is showing promise in clinical trials for Angelman syndrome. @OvidRx @angelman @AngelmanUK Angelman Syndrome International Angelman Day https://t.co/ejMNg9HHVz

  • Mashup Score: 2

    Angelman syndrome is a rare neurodevelopmental disorder caused by a genetic mutation – usually a mutation in the ubiquitin protein ligase E3a (UBE3A) gene – that leads to a reduction in UBE3A protein.

    Tweet Tweets with this article
    • Dr. Amit Rahkit, CMO at Ovid Therapeutics Inc. discusses OV101, a GABAA agonist that is showing promise in clinical trials for Angelman syndrome. @OvidRx @angelman @AngelmanUK Angelman Syndrome International Angelman Day https://t.co/ejMNg9HHVz